Drug intelligence / Profile preview

TRB-051

Development stage: Unknown
Lead developer: Eli Lilly

Overview

TRB-051 is a novel biological therapeutic under development for the treatment of autoimmune and inflammatory diseases. It is designed to modulate regulatory T cells (Tregs) and immune effector cells, aiming to restore immune homeostasis at sites of inflammation. The drug was discovered using TrexBio’s proprietary Deep Biology platform, which maps regulatory T cell behavior in human tissue to identify new immune-regulatory pathways for therapeutic intervention. TRB-051 is being developed through a collaboration between TrexBio and Eli Lilly, with clinical development currently in Phase I trials for autoimmune disorders and inflammation[1][3][4][5]. The precise molecular target or detailed mechanism beyond "regulatory T cell modulation" has not been publicly disclosed as of July 2024.

Other names: TRB 051TRB051TRB-051

Beyond the preview

Go deeper on TRB-051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRB-051.

Explore the full profile